Hemcheck Sweden AB has signed an exclusive distribution agreement with Cruinn Diagnostics, a leading distributor of laboratory and medical equipment in Ireland. The agreement will be in force from July and valid until the end of June 2024, concerning the Irish market. Cruinn Diagnostics has committed to an initial purchase order of readers and one-time tests for a value of 8,000 EUR.
– Cruinn Diagnostics is a well-established distributor in Ireland representing well known global companies, while having a focus on pre-analytics. We believe that they are a very good partner for us in Ireland and we look forward to starting the collaboration, says Joen Averstad, CEO of Hemcheck.
– Hemcheck has a very interesting solution for pre-analytics which fits well into our portfolio, and we think there are good opportunities for the products in the market. We look forward to starting the efforts to approach customers, says Sean McGeown, Director Medical Division of Cruinn Diagnostics.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
About Cruinn Diagnostics
Cruinn Diagnostics is an Irish owned company established in 1998. It’s one of Ireland’s leading distributors of Laboratory supplies and equipment to the Clinical, Industrial, Pharmaceutical, Veterinary, University and Research industries. It is a partner in the local market to global companies such as Siemens Healthineers, Greiner Bio-One, Westmed and Cepheid.
Read more at http://www.cruinndiagnostics.ie/
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.